ProKidney financials
$1.63+1.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $893.0K | $76.0K | $0.00 | $0.00 |
| Gross profit | $893.0K | $76.0K | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | — | — |
| Operating income | -$165.0M | -$183.7M | -$151.5M | -$153.0M |
| Net income | -$69.0M | -$61.2M | -$35.5M | -$14.4M |
| Net margin | −7725.2% | −80507.9% | — | — |
| Diluted EPS | $-0.52 | $-0.62 | $-0.57 | $-0.23 |
| EBITDA | -$158.4M | -$178.2M | -$147.7M | -$150.0M |
| Operating cash flow | -$120.1M | -$126.4M | -$90.1M | -$77.1M |
| Free cash flow | -$135.3M | -$155.9M | -$124.3M | -$78.9M |
| Diluted shares | 133.9M | 97.9M | 61.7M | 61.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $108.5M | $99.1M | $60.6M | $490.3M |
| Short-term investments | $161.5M | $259.2M | $302.3M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $335.6M | $441.1M | $420.6M | $518.0M |
| Total liabilities | $34.8M | $39.4M | $29.2M | $13.1M |
| Shareholders' equity | -$1.01B | -$995.0M | -$1.10B | -$1.10B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology